Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
The Journal of Experimental Medicine|August 3, 2016
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosisSrdan Verstovsek, Taghi Manshouri, Darrell Pilling, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Nature|July 24, 2012
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapyPriya Koppikar, Neha Bhagwat, Outi Kilpivaara, et al.
NPJ Precision Oncology|May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemiaChristopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Cell Stem Cell|July 5, 2014
Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent mannerLin Wang, Huajia Zhang, Sonia Rodriguez, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pageof 9